IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

POTOMAC, MD / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced it will demonstrate its Agentic Harmonization Assistant ("AHA"), an artificial intelligence platform designed to automate the integration and analysis of complex biomedical datasets, at the Alzheimer's & Parkinson's Diseases Conference (ADPD) 2026.

The demonstration will take place in collaboration with the Alzheimer's Disease Data Initiative (ADDI), a global data-sharing platform supported by Gates Ventures and leading research institutions focused on accelerating discoveries in neurodegenerative disease.

AHA is an agent-based AI platform designed to harmonize fragmented datasets across multiple studies, including clinical trial data, imaging, and other biomedical information. Data harmonization remains one of the most time-consuming steps in Alzheimer's research, often requiring months of manual preparation before meaningful analysis can begin. By automating this process, AHA is designed to significantly reduce the time required to prepare large datasets for analysis.

"Artificial intelligence is becoming an increasingly important component of modern biomedical research," said Ram Mukunda, CEO of IGC Pharma. "Demonstrating AHA within the ADDI ecosystem at ADPD provides an opportunity to showcase how AI-driven data integration can accelerate insights from complex datasets while strengthening our in-house analytical capabilities and advancing our clinical programs toward key milestones." Advanced data integration capabilities such as AHA may enhance analysis of complex clinical datasets and support the continued development of the Company's lead drug candidate, IGC-AD1, currently being evaluated in the ongoing Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease.

The Company also believes that scalable platforms capable of harmonizing large biomedical datasets may create future monetization opportunities to support pharmaceutical companies and global research collaborations working with complex neurodegenerative disease datasets.

Participation in ADPD reflects the Company's broader strategy of integrating artificial intelligence, advanced data analytics, and therapeutic development to accelerate innovation in Alzheimer's disease.

About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

SOURCE: IGC Pharma, Inc.